Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Neurocrine Medical Information Call Center
- Phone Number: 1-877-641-3461
- Email: medinfo@neurocrine.com
Study Locations
-
-
-
Cherven Bryag, Bulgaria, 5980
- Recruiting
- Neurocrine Clinical Site
-
Plovdiv, Bulgaria, 4004
- Recruiting
- Neurocrine Clinical Site
-
Sofia, Bulgaria, 1164
- Recruiting
- Neurocrine Clinical Site
-
Varna, Bulgaria, 9020
- Recruiting
- Neurocrine Clinical Site
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Recruiting
- Neurocrine Clinical Site
-
-
-
-
Arkansas
-
Bryant, Arkansas, United States, 72022
- Recruiting
- Neurocrine Clinical Site
-
-
California
-
Chino, California, United States, 91710
- Recruiting
- Neurocrine Clinical Site
-
Fountain Valley, California, United States, 92708
- Recruiting
- Neurocrine Clinical Site
-
Huntington Beach, California, United States, 92648
- Recruiting
- Neurocrine Clinical Site
-
Long Beach, California, United States, 90807
- Recruiting
- Neurocrine Clinical Site
-
San Diego, California, United States, 92123
- Recruiting
- Neurocrine Clinical Site
-
Temecula, California, United States, 92591
- Recruiting
- Neurocrine Clinical Site
-
Torrance, California, United States, 90501
- Recruiting
- Neurocrine Clinical Site
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Recruiting
- Neurocrine Clinical Site
-
Bonita Springs, Florida, United States, 34134
- Recruiting
- Neurocrine Clinical Site
-
Hialeah, Florida, United States, 33012
- Recruiting
- Neurocrine Clinical Site
-
Hialeah, Florida, United States, 33013
- Recruiting
- Neurocrine Clinical Site
-
Miami, Florida, United States, 33176
- Recruiting
- Neurocrine Clinical Site
-
Orange City, Florida, United States, 32763
- Recruiting
- Neurocrine Clinical Site
-
Port Charlotte, Florida, United States, 33980
- Recruiting
- Neurocrine Clinical Site
-
Tampa, Florida, United States, 33629
- Recruiting
- Neurocrine Clinical Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Recruiting
- Neurocrine Clinical Site
-
Marietta, Georgia, United States, 30060
- Recruiting
- Neurocrine Clinical Site
-
-
Illinois
-
Naperville, Illinois, United States, 60563
- Recruiting
- Neurocrine Clinical Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Recruiting
- Neurocrine Clinical Site
-
Bloomfield Hills, Michigan, United States, 48302
- Recruiting
- Neurocrine Clinical Site
-
-
Missouri
-
Saint Charles, Missouri, United States, 63304
- Recruiting
- Neurocrine Clinical Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68526
- Recruiting
- Neurocrine Clinical Site
-
-
New York
-
Commack, New York, United States, 11725
- Recruiting
- Neurocrine Clinical Site
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Recruiting
- Neurocrine Clinical Site
-
Fairlawn, Ohio, United States, 44333
- Recruiting
- Neurocrine Clinical Site
-
-
Texas
-
Austin, Texas, United States, 78754
- Recruiting
- Neurocrine Clinical Site
-
Fort Worth, Texas, United States, 76104
- Recruiting
- Neurocrine Clinical Site
-
Houston, Texas, United States, 77030
- Recruiting
- Neurocrine Clinical Site
-
Stafford, Texas, United States, 77477
- Recruiting
- Neurocrine Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Medically confirmed diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder (MDD) as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for at least 3 months prior to screening.
- Medically confirmed diagnosis of neuroleptic-induced TD as defined in the DSM-5 for at least 3 months prior to screening.
- Moderate or severe TD (AIMS Item 8, severity of abnormal movement overall) as assessed by a blinded, external AIMS video reviewer using a video recording of the participant's AIMS assessment administered at the clinical site by a blinded, certified site AIMS rater. The AIMS dyskinesia total score (sum of Items 1 to 7) must be ≥6 as assessed by the blinded, external AIMS video reviewer.
Key Exclusion Criteria:
- Comorbid parkinsonism (drug-induced or otherwise) or more than a minimal level of extrapyramidal signs/symptoms, as documented by a score on the Modified Simpson-Angus Scale (mSAS) (excluding Items 8 and 10) >6 at screening or Day -1 (baseline) or a score >3 in any one item (excluding Items 8 and 10).
- Barnes Akathisia Rating Scale (BARS) global clinical assessment score ≥2 at screening or Day -1.
- Brief Psychiatric Rating Scale (BPRS) total score ≥50 at screening or Day -1.
- Hospitalized for schizophrenia, schizoaffective disorder, bipolar disorder, or MDD within 6 months of screening.
- Participant has an unstable medical condition or unstable chronic disease.
- Any known history of neuroleptic malignant syndrome (NMS).
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NBI-1065890
Participants will receive NBI-1065890. |
Oral administration |
|
Placebo Comparator: Placebo
Participants will receive placebo matching NBI-1065890. |
Oral administration |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 8 Based on the Blinded Central AIMS Video Raters' Assessment
Time Frame: Baseline and Week 8
|
Baseline and Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants Who Are a Clinical Global Impression - Improvement (CGI-I) Responder 1 at Week 8
Time Frame: Week 8
|
Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Development Lead, Neurocrine Biosciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NBI-1065890-TD2033
- 2025-524104-30-00 (Ctis)
- 2025 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.